Cynthia Seidel-Dugan - Jan 6, 2022 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Role
Chief Scientific Officer
Signature
/s/ Reid Leonard, Attorney-in-fact
Stock symbol
HOWL
Transactions as of
Jan 6, 2022
Transactions value $
$111,838
Form type
4
Date filed
1/14/2022, 04:58 PM
Next filing
Jan 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HOWL Common Stock Options Exercise $37.8K +24.2K +19.33% $1.56 149K Jan 12, 2022 Direct
transaction HOWL Common Stock Options Exercise $74.1K +15.5K +10.4% $4.77 165K Jan 12, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOWL Stock Option (right to buy) Award $0 +79.5K $0.00 79.5K Jan 6, 2022 Common Stock 79.5K $11.55 Direct F1
transaction HOWL Stock Option (right to buy) Options Exercise $0 -24.2K -39.58% $0.00 36.9K Jan 12, 2022 Common Stock 24.2K $1.56 Direct F2
transaction HOWL Stock Option (right to buy) Options Exercise $0 -15.5K -15.66% $0.00 83.6K Jan 12, 2022 Common Stock 15.5K $4.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026.
F2 The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024.
F3 The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.